Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Treasury Shares (2018 - 2025)

Addex Therapeutics' Treasury Shares history spans 8 years, with the latest figure at $1.3 million for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 27.91% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 27.91% increase, with the full-year FY2025 number at $1.2 million, up 23.31% from a year prior.
  • Treasury Shares came in at $1.3 million for Q4 2025, up from $992790.7 in the prior quarter.
  • The five-year high for Treasury Shares was $12.7 million in Q4 2021, with the low at $992790.7 in Q4 2024.
  • Historically, Treasury Shares has averaged $4.5 million across 5 years, with a median of $1.3 million in 2025.
  • Biggest five-year swings in Treasury Shares: skyrocketed 88.75% in 2021 and later crashed 84.27% in 2023.
  • Year by year, Treasury Shares stood at $12.7 million in 2021, then crashed by 48.65% to $6.5 million in 2022, then tumbled by 84.27% to $1.0 million in 2023, then fell by 3.18% to $992790.7 in 2024, then grew by 27.91% to $1.3 million in 2025.
  • Business Quant data shows Treasury Shares for ADXN at $1.3 million in Q4 2025, $992790.7 in Q4 2024, and $1.0 million in Q4 2023.